These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37729600)

  • 1. Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain Metastases.
    Mahashabde R; Bhatti SA; Martin BC; Painter JT; Rodriguez A; Ying J; Li C
    JCO Oncol Pract; 2023 Nov; 19(11):1009-1019. PubMed ID: 37729600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases.
    Mahashabde RV; Bhatti SA; Martin BC; Painter JT; Rodriguez A; Ying J; Li C
    Transl Lung Cancer Res; 2024 Jul; 13(7):1620-1634. PubMed ID: 39118898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents.
    Yang D; Munai E; Zeng S; Tao D; Yuan Z; Du L; Zhou W; Wu Y; Zhu XD
    Cancer Immunol Immunother; 2024 Sep; 73(11):226. PubMed ID: 39237636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
    Front Immunol; 2021; 12():697298. PubMed ID: 34858389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S; Ren F; Meng X
    Front Immunol; 2022; 13():955944. PubMed ID: 36238280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S; Komiya T; Powell E
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.
    Spence MM; Hui RL; Chang JT; Schottinger JE; Millares M; Rashid N
    J Manag Care Spec Pharm; 2017 Feb; 23(2):195-205. PubMed ID: 28125366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
    Liang X; Xiao H; Li H; Chen X; Li Y
    Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
    Kim RY; Li Y; Marmarelis ME; Vachani A
    Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Real-world data from 86 173 patients.
    Takamori S; Shimokawa M; Komiya T
    Thorac Cancer; 2021 Nov; 12(21):2943-2948. PubMed ID: 34612011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
    Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
    Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
    Peng TR; Lin HH; Tsai FP; Wu TW
    Thorac Cancer; 2021 Nov; 12(21):2873-2885. PubMed ID: 34545685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
    Liu T; Wu S; Fang W; Li H; Su L; Qi G; Li H; Liu Y
    PLoS One; 2023; 18(4):e0283719. PubMed ID: 37071610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
    Molife C; Brnabic A; Stefaniak VJ; Belger MA; Gruver K; Chen JV; Souri S; Blumenschein GR
    Immunotherapy; 2023 Mar; 15(4):293-309. PubMed ID: 36748406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer.
    Rong Y; Bentley JP; Bhattacharya K; Yang Y; Chang Y; Earl S; Ramachandran S
    Cancer Med; 2024 Jan; 13(1):e6879. PubMed ID: 38164655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.